Compound ID | 217

Update compound information

Ridinilazole

Synonym(s): SMT 19969

Class: Small molecule antibacterial agent

Agent Type: Synthetic; Small molecule; Direct acting;
Spectrum of activity: Gram-positive
Mechanism of action: DNA synthesis inhibitor. DNA minor groove binder; binds with AT sequence of DNA and additionally inhibits energy metabolism
Target Pathogen: Active against Clostridium difficile infection
Description: Synthetic compound; does not meet superiority in sustained clinical response but reduces recurrent Clostridioides difficile infection and preserves microbiome compared to vancomycin
Institute where first reported: Summit Corp, UK; University of Hertfordshire
Year first mentioned: 2011
Highest developmental phase: Phase 3
Development status: Active
Chemical structure(s):
Click here for structure editor
Molecular weight: 388.42
Iso. SMILES: C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6
InChI Key: UHQFBTAJFNVZIV-UHFFFAOYSA-N
Can. SMILES: C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(C5=CC=NC=C5)N4)NC(=N2)C6=CC=NC=C6
InChI: InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/16659285
Guide to Pharmacology: ridinilazole
Citations:
  • http://aac.asm.org/content/57/10/4872.full
  • https://www.escmid.org/escmid_publications/escmid_elibrary/?q=SMT+19969&id=2173&L=0&x=26&y=26
  • http://uhra.herts.ac.uk/handle/2299/14738
  • https://www.summittxinc.com/app/uploads/2021/07/ECCMID-2021-Summit-Therapeutics-Ridinilazole-MoA.pdf

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.